OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mascarenhas on the MPD-RC 112 Study in PV and ET

December 30th 2016

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.

Dr. Saenger on Immunotherapy Combinations in Melanoma

December 30th 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.

Dr. Wolchok on Progress After Anti-PD-1 Monotherapy in Melanoma

December 29th 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, 2014 Giant of Cancer Care in Melanoma, discusses an ongoing clinical trial that will explore optimal treatments for patients with melanoma who fail on a PD-1 inhibitor as a single agent.

Dr. Birrer on Patient Preferences for Cervical Cancer Treatment

December 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

December 29th 2016

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

Dr. Daver on Immune Checkpoint Pathways in AML

December 28th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.

Dr. Luke on Ongoing Studies With Immunotherapy in Melanoma

December 28th 2016

Jason J. Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses ongoing studies exploring immunotherapy for the treatment of patients with melanoma.

Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment

December 28th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

Dr. Burtness on Treatment Approaches in HPV-Positive Head and Neck Cancer

December 27th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.

Dr. Puzanov on Sequencing Targeted Therapy and Immunotherapy in Melanoma

December 27th 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.

Dr. Kumar on the Rationale for Studying Venetoclax in Multiple Myeloma

December 26th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the rationale for investigating venetoclax as a treatment for patients with multiple myeloma.

Dr. Braghioli on Molecular Characterization of CRC Tumors

December 26th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses a study exploring the various molecular characteristics of colorectal cancer (CRC) tumors.

Stefani Spranger on the Role of CD8 T Cells in Melanoma

December 23rd 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago Medicine, discusses how the presence or absence of CD8 T cells can affect treatment approaches for patients with melanoma.

Dr. Bekaii-Saab on the Role of Immunotherapy in CRC

December 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with colorectal cancer.

Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer

December 23rd 2016

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.

Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma

December 23rd 2016

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the risks and benefits of combination immunotherapy as treatment for patients with melanoma.

Dr. Kolibaba on Mechanism of Action With Entospletinib in MCL

December 23rd 2016

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses the mechanism of action with entospletinib (GS-9973) and its potential as a treatment for patients with mantle cell lymphoma (MCL).

Dr. Ansell on Promise With Immunotherapy in Hodgkin Lymphoma

December 23rd 2016

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically the CheckMate-039 trial.

Dr. Hamid on Immunotherapy Approaches in Melanoma

December 22nd 2016

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses different immunotherapy approaches that oncologists are currently exploring in melanoma.

Dr. Dadu on Treatment Approaches in Medullary Thyroid Cancer

December 22nd 2016

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches in medullary thyroid cancer.